MedTrace Logo

Have Malaria Infections in Kenya Become Less Responsive to Artemisinin Treatment?

NCT01190371 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2018-02-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether P. falciparum infections in Kilifi District have developed tolerance to the artemisinin class of drugs.

Conditions

Interventions

DRUG

Artesunate

Oral, once daily, 7-day regimen of artesunate 2mg/kg/day

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Heidelberg University

    collaborator OTHER

  • KEMRI-Wellcome Trust Collaborative Research Program

    lead OTHER

Principal Investigators

  • Roma Chilengi · KEMRI Centre for Geographic Medicine Research (Coast), University of Oxford, England

  • Steffen Borrmann · KEMRI Centre for Geographic Medicine Research (Coast), Heidelberg University of Medicine, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-11-30
Completion
2018-12-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01190371 on ClinicalTrials.gov